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Abstract: The approach to studying diet–health relationships has progressively shifted from
individual dietary components to overall dietary patterns that affect the interaction and balance of
low-molecular-weight metabolites (metabolome) and host-enteric microbial ecology (microbiome).
Even though the Mediterranean diet (MedDiet) has been recognized as a powerful strategy to
improve health, the accurate assessment of exposure to the MedDiet has been a major challenge in
epidemiological and clinical studies. Interestingly, while the effects of individual dietary components
on the metabolome have been described, studies investigating metabolomic profiles in response
to overall dietary patterns (including the MedDiet), although limited, have been gaining attention.
Similarly, the beneficial effects of the MedDiet on cardiometabolic outcomes may be mediated through
gut microbial changes. Accumulating evidence linking food ingestion and enteric microbiome
alterations merits the evaluation of the microbiome-mediated effects of the MedDiet on metabolic
pathways implicated in disease. In this narrative review, we aimed to summarize the current
evidence from observational and clinical trials involving the MedDiet by (1) assessing changes in the
metabolome and microbiome for the measurement of diet pattern adherence and (2) assessing health
outcomes related to the MedDiet through alterations to human metabolomics and/or the microbiome.
Keywords: Mediterranean diet; metabolomics; microbiome
1. Introduction
The Mediterranean diet (MedDiet) is a dietary pattern that emphasizes the intake of vegetables,
fruits, nuts, whole grains, fish, and unsaturated fats and vegetable oils (mainly olive oil) and aims
to limit the intake of butter, sweets, and red and processed meat [1,2]. Multiple studies have found
evidence of lower risk and incidence of and mortality from chronic metabolic diseases with adherence
to the MedDiet [3–6]. The United States (US) Department of Agriculture and Health and Human
Services recognized the MedDiet as a healthy dietary pattern in the 2015–2020 Dietary Guidelines for
Americans [7,8], and this dietary pattern has been successfully adapted into workplace interventions [9].
Notwithstanding the MedDiet’s growing acceptance for health improvement, the accurate assessments
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of exposure and adherence to the MedDiet in epidemiological studies and clinical interventions,
respectively, continue to be major hurdles in advancing our understanding of the MedDiet’s efficacy.
Additionally, the underlining molecular and metabolic mechanisms that influence health outcomes in
response to the MedDiet have not been elucidated.
The inherent subjectivity in the self-administered instruments used for dietary adherence/
compliance assessment, such as food frequency questionnaires, multiple-day food records, and 24-h
dietary recall, creates susceptibility to the introduction of bias and errors into data collection,
ultimately impacting study outcomes [10–12]. There is an increasing consensus that employing
objective measurement approaches (e.g., biomarkers and metabolic signatures) and robust research
design (controlling for regression to the mean) concurrently with self-administered instruments may
significantly improve data quality and validate study outcomes. However, logistical challenges,
the economic burden, and the absence of reliable and sensitive biomarkers for dietary patterns,
as opposed to an individual nutrient/ingredient, have limited the inclusion of objective analytical
approaches in study methodologies. In this regard, leveraging rapid advances in high-throughput,
big data omics technologies may overcome such pitfalls in nutritional epidemiology and intervention
studies. Specifically, metabolomics (the study of low-molecular-weight metabolites in biological
samples) and the research of microbiomes (the study of host-enteric microbial ecology) may facilitate
the discovery and validation of specific biomarker signatures of dietary behavior and probe the
complex interactions between food, lifestyle, and disease [13,14]. Generally, the most commonly used
techniques in metabolomics analysis are mass spectrometry (MS), usually coupled with gas or liquid
chromatography, and nuclear magnetic resonance (NMR) spectroscopy [15]. Each of these techniques
has its own advantages and disadvantages. Both can be used to identify the structure of metabolites
and measure the absolute and relative concentrations of metabolites. However, NMR has higher
reproducibility and is more reliable for determining concentrations, while MS is more sensitive [15,16].
As for the analysis of the microbiome, techniques have evolved from culture-dependent methodologies
to novel, next generation sequencing tools. The latter has allowed for the taxonomic and phylogenetic
evaluation of the bacterial community based on 16S RNA gene amplicon analysis [17].
There is a growing body of knowledge on the metabolic signatures of individual food groups,
such as fruit (proline betaine as a biomarker of citrus fruits) [18–22], vegetables (S-methyl-L-cysteine
sulphoxide and its derivatives for cruciferous vegetables) [23–26], and whole grains (urinary excretions
of alkylresorcinols and benzoxazinoid) [23,27–29] (Supplemental Table S1). However, notwithstanding
the scientific interest in the matter, the literature on the metabolomics of overall diet patterns (including
the MedDiet) is limited [30].
The importance of the gut microbiome in food digestion, nutrient metabolism, micronutrient
production, enteric immunity, and gut function have been known for a long time [31,32]. Seminal
papers published in the past two decades have expanded the understanding of the gut microbiome to
overall human health and exposed the multilevel dimensional complexity of the diet–environment–
microbiome–host interactions that impact human health [33–35]. The rapid expansion in this research
area, in this regard, has disrupted the functional locality of the microbiome and highlighted its systemic
effects beyond the gut, which are mediated by a combination of direct (physical) interactions of the
microbes with the host and indirect processes via the production of metabolites, de novo or from
diet. Moreover, the plasticity of the microbial ecology in response to diet and the growing evidence of
the association between an altered ecological profile of the microbiome (dysbiosis) and disease have
positioned the targeted and directed modulation of the gut microbiome as an exciting therapeutic target
for a wide variety of pathologies, including acute infections (Clostridium difficle) [36], chronic illnesses
(metabolic disease) [37], and mental health [38].
Sustained scientific exploration of the direct manipulation of gut ecology has identified strain-level
specificity of microorganisms (e.g., lactic acid bacteria) for different health indications, as well as
diet-derived natural or synthetic compounds that can stimulate colonization (fructooligosaccharides)
and delivery mechanisms (encapsulation) to ensure survival and viability during gastrointestinal
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transit. The relative simplicity of this approach, favorable consumer perception, and historical
correlation of fermented diets with health has allowed for the successful commercial exploitation
of these principles by the food and beverage industry on a global scale. The rapid proliferation of
consumer products (probiotic/prebiotics) and the dramatic growth of the size of this market continue
to raise new instances of regulatory scrutiny and topics of policy debate [39].
The body of knowledge on the ‘indirect’ interactions between diet, the microbiome, and health
via metabolite production is, on the other hand, relatively nascent [40]. The chemical complexity
of diet, gut microbial diversity, and host-related genetic and lifestyle factors have been hurdles that
have impeded investigations that attempt to reliably study even just the interaction of an individual
dietary ingredient with health. Moreover, these challenges are amplified when attempting to delineate
the effects of dietary patterns (e.g., the MedDiet) as opposed to one specific dietary ingredient (e.g.,
polyunsaturated fatty acid (PUFA)) on health outcomes. These problems are compounded when a
potential metabolite of interest is produced both in the host and by the microbiome. For example,
levels of trimethylamine oxide-N-oxide (TMAO) and its precursors choline and carnitine have been
correlated with cardiovascular outcomes. However, establishing the relative contributions of the host,
diet, and microbial dysbiosis have proven to be challenging in nutrition studies.
The application of big data and high-throughput omics approaches have successfully transformed
physical, medical, forensic, and environmental sciences [41–43]. The combination of metabolomics
and the study of the microbiome using powerful big data statistics can be leveraged to improve
our understanding of the relationship between the MedDiet and health. In this narrative review,
we summarize current scientific evidence from epidemiological studies focused on (1) the assessment
of changes in the metabolome and microbiome for the measurement of adherence to the MedDiet
pattern and (2) the understanding of the effect of the MedDiet on health outcomes through alterations
in human metabolomics and/or the microbiome.
2. Metabolomics and the Mediterranean Diet—The Present Status
Strong evidence supports the use of the MedDiet as a preventive strategy to lower the risk
of cardiovascular diseases (CVD) [44–46]. However, the characterization of the dietary pattern
has been hindered due to the complex interactions between the human genome and diet [30,45].
Recent research in nutritional metabolomics has focused on discovering new biomarkers of nutritional
exposure, nutritional status, and nutritional impacts on disease [47]. There is general consensus that
establishing reliable biomarkers is imperative to facilitate the development of “precision nutrition”,
in which omics techniques can be applied to a personalized diet for the prevention and management
of disease. Although relevant scientific literature is emerging on this topic, with several studies
pursuing the identification of metabolic signatures for overall dietary patterns, few have focused
specifically on the MedDiet [30]. Moreover, a collective endeavor in this regard can also be extended to
discover biomarkers of health outcomes following a MedDiet intervention or dietary approaches [48].
Along these lines, this section will summarize the current status of the research on using metabolomics
to assess the MedDiet pattern and to understand the associations between the MedDiet and health.
2.1. Metabolomics Approach as an Assessment of Adherence to the Mediterranean Diet
A recent review of the use of nutritional metabolomics to assess dietary intake found 16
studies on dietary patterns and metabolomics, of which only three specifically assessed the MedDiet
pattern [30]. Here, we include three additional articles regarding metabolomics and dietary patterns
in general [49,50] and four specifically about the MedDiet [51–53]. Metabolomics profiles have been
characterized in multiple dietary patterns, including the New Nordic diet, low-fat diet, low glycemic
index diet, very-low-carbohydrate diet, a diet concordant with World Health Organization (WHO)
healthy eating guidelines, prudent diet, etc. A recent study assessing overall dietary patterns
was a randomized, controlled, crossover study that used a targeted metabolomics method to
assess concentrations of 333 plasma metabolites of three hypocaloric dietary patterns—low-fat,
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low glycemic index, and very-low-carbohydrate diets—to evaluate compliance with each for a 4-week
period [49]. Using four types of constructed, Bayesian network classifiers, the plasma metabolites
that were different from at least one other diet were diacylglycerols (DAG), triacylglycerols (TAG),
and branched-chain amino acids (BCAA) [49]. For example, the low glycemic index diet had an
intermediate concentration of most metabolites (105 out of 152), which differentiated it from the other
two diets [49]. These metabolites included hippurate 5-aminolevulinic acid, pipecolic acid, cytosine,
triacylglycerides, and hydroxyproline [49]. Another study identified two distinct dietary patterns
using dietary and urinary metabolomics data obtained from the National Adult Nutrition Survey [50].
They used two-step cluster analysis in both urine and dietary data and identified in the latter a
“healthy” and an “unhealthy” cluster [50]. Consistent with the previous studies, the authors found
higher levels of hippurate and also betaine, anserine, N-phenylacetylglutamine, 3-hydroxybutyrate,
citrate, tryptophan, and 2-aminoadipate in the healthy cluster [50]. Higher creatinine, glycylproline,
N-aceytalglutamate, and theophylline were found in the unhealthy cluster, and the two dietary
patterns were further supported by subsequent validation in the NutriTech food intake study [50].
Recently, the serum metabolic profile of the Dietary Approaches to Stop Hypertension (DASH)
pattern identified the top 10 most influential known metabolites, which differed significantly between
participants randomly assigned to the DASH diet compared with both the control diet and the fruit
and vegetables diet [54].
With regards to the MedDiet pattern, while still emerging, the evidence about metabolomics
and the MedDiet–health association remains limited [48]. Compared with general dietary patterns,
the number of published studies exploring the metabolomics signatures of the MedDiet is relatively
small. In addition to those studies addressed by Guasch et al. [30], we describe here the evidence
of four additional studies. Table 1 provides a more detailed summary of the evidence from studies
using metabolomics to assess potential biomarkers for the MedDiet. González-Guardia and colleagues
investigated biomarkers in a crossover study with four isocaloric diets: the MedDiet supplemented
with Coenzyme Q10 (Med + CoQ), the MedDiet, the Western diet high in saturated fat, and a low-fat,
high-carbohydrate diet rich in n-3 polyunsaturated fat [55]. Greater urinary hippurate levels after the
adherence to the Med + CoQ diet and greater phenylacetylglycine levels after adherence to the Western
diet high in saturated fat were found in female participants [55]. This higher level of hippurate was
reported to positively correlate with CoQ and plasma β-carotene levels and negatively correlate with
gene expression of transcription factor Nrf2, thioredoxin, superoxide dismutase 1, and the gp91phox
subunit of NADPH (nicotinamide adenine dinucleotide phosphate) oxidase gene expression [55].
Another cross-sectional study, using a targeted metabolomics approach explored the association
between the effect of the interaction between polymorphisms and the MedDiet on the levels of 14
specific serum metabolites that could be related to dietary adherence [56]. These metabolites played
key roles in gene-encoding enzymes modulated by nine previously genotyped polymorphisms [57–59].
The results showed that a 1 unit increase in adherence to the MedDiet pattern was associated with a
5% increase in 5-Methylfolate (5-MTHF) [56]. Finally, another cross-sectional study found that urine
microbial metabolites (phenylacetylglutamine, p-cresol, and 4-hydroxyphenylacetate) defined high
adherence to the MedDiet [60].
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Table 1. Metabolomics as an assessment of the Mediterranean diet (MedDiet) dietary pattern.
Study Design Participants DietaryPattern/Intervention Follow-Up
Biological
Sample/Metabolomics
Approach/Technique
Biomarkers Identified Main Conclusion
Playdon et al.,
2017 [51]
5 nested case-control
studies (within the
Alpha-Tocopherol,
Beta-Carotene
Cancer Prevention
Study)
Male Finnish
smokers n = 1336,
aged 50–69 years
HEI 1 2010, aMED 2,
HDI 3, and BSD 4
3 years
Serum
Untargeted
MS
HEI 2010, HDI and BSD: associated with 17,
11, and 10 identified metabolites, respectively.
aMED: associated with 21 identifiable
metabolites: 4 aminoacids (indolebutyrate,
tryptophan betaine, N-methylproline,
3-Hydroxy-2-ethylpropionate);
1 carbohydrate (threitol); 2 co-factors
(threonate, γ-CEHC 5); 3 xenobiotics
(stachydrine, Phytanate,
ergothionein) 11 lipids
(1-myristoleoylglycerophosphocholine (14:1),
Scyllo-inositol, Mead acid (20:3n -9), g-CEHC,
cis-4-Decenoyl carnitine,
3-Carboxy-4-methyl-5-propyl-2-furanpropanoate,
linoleate (18:2n-6), linolenate (α or γ; 18:3n-3
or 18:3n-6), chiro-inositol, 1-linoleoylglycerol,
DHA, methyl palmitate
The HEI-2010, aMED, HDI,
and BSD were associated
with metabolites correlated
with foods that are used to
evaluate adherence to
each score.
Vázquez-Fresno
et al., 2015 [53]
Parallel-group,
single-blind,
multicenter,
randomized,
controlled feeding
trial. A follow-up in
the PREDIMED 6
study.
Clinically
identified
non-diabetic
participants at
high CVD 7 risk
n = 98 aged
55–80 years
MedDiet 8 + EVOO
9 (n = 41)
(MedDiet + nuts
(n = 27)
LFD 10 (n = 30)
3 years
Urine (baseline, 1 year,
and 3 year of the
intervention)
Untargeted
NMR
MedDiet: carbohydrates (3-HB 11, citrate, and
cisaconitate), creatine, creatinine, amino acids
(proline, N-acetylglutamine, glycine,
branched-chain amino acids, and derived
metabolites), lipids (oleic and suberic acids),
and microbial cometabolites (PAGN 12
and p-cresol)
LFD: hippurate, TMAO 13, anserine, histidine
and derivates (3-MH 14, 1-MH, carnosine,
anserine), and xanthosine.
The MedDiet groups had
distinct metabolic profiles
compared to the baseline
and control group related to
carbohydrate and lipid
metabolism, amino acids,
and microbial cometabolites
(PAGN and p-cresol)
Bondia-Pons
et al., 2015 [52]
Randomized
controlled dietary
intervention
Individuals with
high BMI and at
least two features
of metabolic
syndrome.
N = 72
RESMENA 15 diet (n
= 47) (based on
MedDiet). 7
meals/day. (40%
CHO 16, 30%protein,
30% lipid).
Control diet (n = 45)
(American Heart
Association
guidelines). 5
meals/day (55%
CHO 55%, 15%
protein, 30% lipid)
6-month
(2-month
nutritional
learning
followed by a
4-month
self-control
period)
Plasma
Non-targeted
MS-Liquid
Lipids, mainly phospholipids and
lysophospholipids.
lactic acid, L-isoleucine, alloisoleucine,
hydroxyvaleric acid, hypaphorine,
paraxanthine, hippuric acid, furancarboxylic
acid, LysoPC 17 (14:0), LysoPC (20:5), LysoPC
(16:1), LysoPC (22:6), LysoPE (20:4), LysoPE 18
(18:2), LysoPC (16:0), Linoleamide, LysoPC
(20:3), LysoPE (18:1), LysoPC (18:1), LysoPC
(20:4), Eicosapentaenoic acid, LysoPC (15:0),
Lithocholic acid, Oleamide, 1-Monopalmitin,
LysoPC (18:0), GPL 19 containing (18:2),
Palmitic acid, PC 20, and PE 21
The major discriminative
markers between the two
groups were the
plasmalogen PC (P
22-18:1/20:3) after 2 months
and palmitic acid after
6 months.
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Table 1. Cont.
Study Design Participants DietaryPattern/Intervention Follow-Up
Biological
Sample/Metabolomics
Approach/Technique
Biomarkers Identified Main Conclusion
González-Guardia
et al., 2015 [55]
Randomized,
crossover
Men (n = 5) and
women (n = 5)
aged 65 years or
older.
n = 10
MedDiet+ 200mg/d
CoQ 23;
MedDiet without
CoQ
Western diet rich in
SFA 24;
Low-fat,
high-carbohydrate
diet enriched in n-3
PUFA25.
4 weeks
Urine and plasma
Targeted
NMR
CoQ and β-carotene plasma
levels and isoprostanes urinary levels
were determined.
Higher levels of hippurate and lower levels of
phenylacetylglycine were found when
comparing the MedDiet + CoQ and the SFA.
The MedDiet supplemented
with CoQ is associated with
increased levels of excreted
hippurate and decreased
levels of
phenylacetylglycine
compared with a
SFA-rich diet.
Kakkoura et al.,
2017. [56]
Cross-sectional
study.
Greek-Cypriot
control women
who have
previously
participated in the
population-
based case-
control study of
BC, MASTOS [61].
n = 564
MedDiet (highest
and lowest
adherence to
MedDiet)
N/A Serum Targeted.UPLC-MS/MS
5-MTHF 26, riboflavin,
FMN 27, PA, methionine, methionine
sulfoxide, SAM 28, SAH 29,
total HCY 30, cystathionine, total cysteine,
γ-glu-cys, total GSH 31,
and α-hydroxybutyrate.
Higher adherence to the
MedDiet was associated
with an increase in
antioxidant-related
metabolites, 5-MTHF.
1 HEI: Healthy Eating Index. 2 aMED: Mediterranean diet score. 3 HDI: the WHO Healthy Diet Indicator. 4 BSD: the Baltic Sea Diet. 5 CEHC: carboxyethyl hydroxychroman.
6 PREDIMED: Prevención con Dieta Mediterránea. 7 CVD: cardiovascular disease. 8 MedDiet: Mediterranean diet. 9 EVOO: extra virgin olive oil. 10 LFD: a control, low-fat
diet. 11 HB: hydroxybutyrate. 12 PAGN: phenylacetylglutamine. 13 TMAO: Trimethylamine N-oxide. 14 MH: Methylhistidine. 15 RESMENA: Metabolic Syndrome Reduction in
Navarra. 16 CHO: Carbohydrates. 17 LysoPC: lysophosphatidylcholine. 18 LysoPE: lysophosphatidylethanolamine. 19 GPL: glycerophospholipid. 20 PC: phosphatidylcholine. 21 PE:
phosphatidylethanolamine. 22 P: plasmalogen. 23 CoQ: coenzyme Q. 24 SFA: Saturated fatty acids. 25 PUFA: polyunsaturated fatty acids. 26 5-MTHF: L-Methylfolate. 27 FMN: flavin
mononucleotide. 28 SAM: S-adenosylmethionine. 29 SAH: S-adenosylhomocysteine. 30 HCY: Homocysteine. 31 GSH: glutathione. MS: Mass spectrometry; DHA: Docosahexaenoic Acid;
NMR: nuclear magnetic resonance; BMI: Body mass index. 5-MTHF: 5-Methylfolate.
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2.2. Metabolomics, the Mediterranean Diet, and the Association with Health
Several studies have investigated the role of metabolites on the etiological and patho-physiological
processes implicated in cardiovascular disease and related morbidities. For example, in a meta-analysis,
the results from prospective studies support robust positive associations of BCAAs (leucine, isoleucine,
and valine) and aromatic amino acids (tyrosine and phenylalanine) and inverse associations of glycine
and glutamine with incident type 2 diabetes (T2D) [62]. Similarly, the results from a systematic review
showed that the metabolites associated with CVD risk were acylcarnitines and dicarboxylacylcarnitines,
TMAO, and several amino acids, such as phenylalanine, glutamate, and several lipid classes [63].
Although it is known that the MedDiet is associated with lower risk of CVD, attempts to correlate
MedDiet-adherence-derived metabolites with CVD-associated biomarkers and clinical outcomes have
proved inconclusive. For example in the randomized, controlled OmniHeart study, blood pressure
was found to be significantly associated with six urinary metabolites reflecting dietary intake [64],
and among those following the New Nordic Diet, higher levels of vaccenic acid and 3-hydroxybutanoic
acid were related to higher weight loss, while higher concentrations of salicylic, lactic, and N-aspartic
acids and 1,5-anhydro-d-sorbitol were related to lower weight loss [65]. Evidence from studies
specifically addressing the MedDiet come from the PREDIMED (Prevención con Dieta Mediterránea)
study (a randomized, controlled trial with a 4.8-year follow-up) that has focused on baseline and
1-year changes in metabolites after following the MedDiet supplemented with extra virgin olive oil
(EVOO) or nuts in comparison with a low-fat diet and its association with CVD and T2D. In this section,
we summarized the evidence of metabolomics relating to the MedDiet pattern and its association with
CVD and T2D (Table 2).
All the studies evaluating the metabolites in the PREDIMED study followed a nested case–cohort
study design, by which between 10–20% of the original study participants were randomly selected
along with all the incident cases of CVD (n = 229–233) or diabetes (n = 251). The studies focusing
on CVD, were assessing most of the metabolites already identified to be associated with CVD,
including the following: BCAAs, choline pathway, different classes of lipids, ceramides, tryptophan,
acylcarnitines, and glutamine. Higher concentrations of short and medium acylcarnitines [66], choline
pathway metabolites (TMAO, betaine, choline, phosphocholine, and α-glycerophosphocholine) [67],
kynurenine risk score [68], ceramides [69], glutamine [70], and some lipids (monoacylglicreol
(MAG), DAG, short-chain triacylglycerol (TAG)) [71] were associated with increased CVD risk at
the baseline. On the contrary, higher tryptophan, cholesterol esters (CE), glutamine/glutamate
ratio, and polyunsaturated phosphatidylcholines were associated with lower risk of CVD (Figure 1).
When the one-year changes in the metabolites were assessed, their associations with CVD were less
clear. Only changes in acylcarnitynes [66] and phosphatidylethanolamine [71] were associated with
the composite of CVD risk. Similarly, the role of the MedDiet in mediating the association seemed
to be more significant when baseline metabolites were assessed. The MedDiet counteracted the
deleterious effect of the high tryptophan risk score [68] and modulated the risk at the baseline for
acylcarnitines [66], choline [67], ceramides [69], and glutamine [70], demonstrating the cardioprotective
effects of the MedDiet by shedding some light on the biological mechanisms.
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Figure 1. Depiction of the metabolites associated with adherence to the MedDiet in the absence
and presence of disease. All the increases in the metabolite profiles are identified with an up arrow,
and all the decreases are identified with a down arrow. In general, the results from the PREDIMED
study suggest t at the MedDiet may counteract the deleterious effect of metabolites related to CVD
an diabetes and that it is able to reduce the levels f so e of them (e.g., tryptophan nd BCAA)
after one-year of intervention in comparison with the control group. 1 MedDi t: M diterranean
diet. 2 PAGN: phenylacetylglutami e. 3 BCAA: branche -chain amino acids. 4 CVD: cardiovascular
diseas . 5 TMAO: Trimethylamine N-oxide. 6 CE: cholesterol ster. 7 MAG: monoacylglycerols.
8 DAG: dia ylglycerols. 9 TAG: Triacylglyce l. 10 T2D: type 2 diabetes. 11 AAA: aro atic amino acid.
12 NMMA: N-methylmalonamic acid. 13 TAG: triacylglycerols; 14 PE: phosphatidylethanolamines.↓:
decreased with the consumption of MedDiet. ↑: increased with consumption of MedDiet.
As with CVD, some metabolites have been associated with T2D (nested case–cohort
PREDIMED study with around 250–251 cases of T2D) (Table 2). Higher concentrations of BCAAs,
aromatic amino acid (phenylalanine and tyrosine) [72], changes in ornitin and citrulline [73],
triacylglycerols (TAG), DAG, phosphatidylethanolamines (PE) [74], tryptophan, and one-year changes
in quinolic [75] were associated with higher risk of T2D. In contrast, TMAO, L-carnitine, betaine,
α-glycerophosphocholine [76], and arginine: asymmetric dimethylarginine (ADMA) [73] were
associated with lower risk of T2D. Only BCAAs, aromatic amino acid, and tryptophan interacted with
the MedDiet + EVOO intervention to modulate the risk of T2D [72] (Figure 1).
In summary, the above studies demonstrated extensive variability in the metabolomic signatures
of the MedDiet pattern, disease biomarkers, and clinical health outcomes (Figure 1). These may
result from disparities in the biological samples (urine versus plasma/serum), the frequency of
metabolite analysis, the analytical methods/techniques, inter-laboratory variability, and differences
in the study design, the participant health status, and the MedDiet composition (e.g., Mediterranean
countries have a higher consumption of olive oil than non-Mediterranean countries). Furthermore,
different self-reported dietary assessment tools and inherent recall errors and biases exacerbate
metabolomic profile inconsistencies across different MedDiet studies. Future approaches should
attempt to standardize the above stated methodological discrepancies and also validate the findings in
wider populations, especially for the MedDiet, for which little information is available outside of the
PREDIMED study.
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Table 2. Metabolomics, the Mediterranean diet pattern, and its association with CVD and T2D.
Author Study Design Study Population DietaryPattern/Intervention Follow-Up
Biological
Sample/Metabolomics
Approach
Metabolites Examined Main Conclusion
Guasch-Ferré
et al., 2016 [66]
Case–cohort
study within the
PREDIMED 1
study
Participants aged
55–80 years at high
risk of CVD 2.
n = 980 (229 cases
CVD cases).
MedDiet 3 groups:
(MedDiet + EEVO
4 and MedDiet +
mixed nuts.
Control group:
low-fat diet.
4.8 years
Plasma. (baseline and
after 1 year)
Targeted
28 acylcarnitines:
short-chain acylcarnitines
(C2–C7),
medium-chain acylcarnitines
(C8–C14), and long-chain
acylcarnitines (C16–C26).
An increased level of acylcarnitines metabolic
profiles is independently associated with total
CVD risk and risk of stroke.
MedDiet interventions may attenuate the
association between acylcarnitines and CVD risk.
Guasch-Ferré
et al., 2017 [67]
Case–cohort
study within the
PREDIMED
study
Participants aged
55–80 years at high
risk of CVD.
n = 980 (229 CVD
cases)
MedDiet groups:
(MedDiet + EEVO
and MedDiet +
mixed nuts.
Control group:
low-fat diet.
4.8 years
Plasma (baseline and
after 1 year)
Targeted
Metabolites of the choline
pathway: TMAO 5, betaine,
choline, phosphocholine,
and a-glycerophosphocholine.
A choline metabolite score
was created.
The baseline choline metabolite score was
associated with increased risk of CVD.
The one-year changes in plasma metabolites were
not significantly associated with CVD.
The participants in the highest metabolite score
quartile and assigned to low-fat diets had higher
risk of CVD than those in the lowest metabolite
quartile and in the MedDiet group.
No significant interaction was found between the
continuous choline score, the betaine/choline
ratio, and the intervention group and CVD
Yu et al., 2017
[68]
Case–cohort
study within the
PREDIMED
study, controlled
trial
Participants aged
55–80 at high risk
of CVD.
n = 985 (231 CVD
cases)
MedDiet groups:
(MedDiet + EEVO
and MedDiet +
mixed nuts.
Control group:
low-fat diet.
4.7 year
Plasma
(baseline and after
1 year)
Targeted
Tryptophan, kynurenine,
kynurenic acid,
3-hydroxyanthranilic acid, and
quinolinic acid concentrations.
A KRS 6 was created.
The positive association between the KRS and
CVD risk is stronger in the control group,
indicating that the MedDiet may attenuate the
effect of a high KRS score.
Toledo et al.,
2017 [77]
Case–cohort
study within the
PREDIMED
study
Participants aged
55–80 years at high
risk of CVD.
n = 983 (230 CVD
cases)
MedDiet groups:
(MedDiet + EEVO
and MedDiet +
mixed nuts.
Control group:
low-fat diet.
4.8 years
Plasma (baseline and
after 1 year)
Untargeted lipidome
202 lipid species
The baseline concentrations of cholesterol esters
(CEs) were inversely associated with CVD. The
MedDiet interventions resulted in changes in the
lipidome at 1 year; however, they were not found
to be associated with subsequent CVD risk.
Lipid metabolites with a longer acyl chain and a
higher number of double bonds at the baseline
were significantly and inversely associated with
the risk of CVD.
Wang et al.,
2017 [69]
Case–cohort
study within the
PREDIMED
study
Participants aged
55–80 years at high
risk of CVD.
n = 980 (230 CVD
cases)
MedDiet groups:
(MedDiet + EEVO
and MedDiet +
mixed nuts.
Control group:
low-fat diet.
≤7.4 years
Plasma (baseline and
after 1 year)
Targeted
4 different ceramides: ceramide
(d 7 18:1/16:0), ceramide
(d18:1/22:0), ceramide
(d18:1/24:0), and ceramide
(d18:1/24:1). A ceramide score
was calculated.
The ceramide score was positively associated with
the risk of CVD.
The MedDiet may alleviate the potential negative
effects of increased plasma ceramide levels
on CVD.
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Table 2. Cont.
Author Study Design Study Population DietaryPattern/Intervention Follow-Up
Biological
Sample/Metabolomics
Approach
Metabolites Examined Main Conclusion
Zheng et al.,
2017 [70]
Case–cohort
study within the
PREDIMED
study
Participants aged
55–80 years at high
risk of CVD.
n = 980 (788
subcohort, 192
incident external
cases)
MedDiet groups
(intervention diets):
(MedDiet + EEVO
and MedDiet +
mixed nuts.
Control group:
low-fat diet.
4.8 years
Plasma (baseline and
after 1 year)
Targeted
Glu14 8 Gln15 9, Glu/Gln ratio
No significant effect of the
intervention on one-year changes
in the metabolites. No effect of
the changes themselves on the
CVD risk was apparent.
A positive association between Glu levels and
CVD risk (43% increased risk) and a negative
association between Gln/Glu and risk of CVD
(25% decreased risk) were found.
The interventions effectively lowered CVD risk for
the participants with high baseline Glu, while no
effects were found among the participants with
low baseline Glu.
Razquin
et al., 2018
[71]
Unstratified
case–cohort
design within
the PREDIMED
study.
n = 983
participants (233
CVD cases).
MedDiet groups:
(MedDiet + EEVO
and MedDiet +
mixed nuts.
Control group:
low-fat diet.
4.8 years Plasma (baseline andafter 1 year)
Lipid group A: PC 10 (PCs,
LysoPC11s and PC-plasmalogens
with ≥5 double bonds);
CE 12 with N3 double bonds; and
TAG 13 with ≥52 carbon atoms
containing ≥6 double bonds.
Lipid group B: MAG 14; DAG 15;
short-chain, TAGs containing ≤4
double bonds; PEs 16 except those
with saturated fatty acids;
hydroxyPC.
PC, CE, long-chain TAG, MAG
and DAG, short-chain TAG, PE,
and Hpc 17 scores were
calculated.
The metabolites from lipid group A were inversely
associated with CVD; the metabolites from lipid
group B were directly associated with CVD. The
baseline phosphatidylethanolamines (PEs) and
their one-year changes tended to be associated
with higher CVD risk.
No significant effect of the MedDiet intervention
was found on the metabolite scores.
Ruiz-Canela
et al., 2016
[78]
Case–cohort
study within the
PREDIMED
study
n = 970 (226 CVD
cases)
MedDiet groups:
(MedDiet + EEVO
and MedDiet +
mixed nuts.
Control group:
low-fat diet.
4.8 years Plasma (baseline andafter 1 year) BCAAs
Higher concentrations of baseline BCAAs were
associated with increased risk of CVD.
No significant effect of the intervention on
one-year changes in BCAAs or any association
between one-year changes in BCAAs and CVD
were observed.
Yu et al.,
2017 [73]
Case–cohort
study within the
PREDIMED
study
n = 984 (231 CVD
cases)
MedDiet groups:
(MedDiet +EEVO
and MedDiet +
mixed nuts.
Control group:
low-fat diet.
4.7 years Plasma (baseline andafter 1 year)
arginine, ornithine, citrulline,
ADMA 18, symmetric
dimethylarginine (SDMA 19), and
NG-monomethylarginine
(NMMA 20)
A higher baseline arginine/asymmetric
dimethylarginine ratio was associated with lower
CVD incidence. No significant modification by the
MedDiet after one-year intervention
was observed.
Guasch-Ferre
et al., 2018
[79]
Case–cohort
study in the
PREDIMED
study
n = 892
participants (251
T2D cases)
MedDiet groups:
(MedDiet + EEVO
and MedDiet +
mixed nuts.
Control group:
low-fat diet
3.8 years Plasma (baseline andafter 1 year)
Short-chain acylcarnitines
(C2–C7),
medium-chain acylcarnitines
(C8–C14), and long-chain
acylcarnitines (C16–C26).
The acylcarnitines profile, specifically short- and
long- chain acylcarnitines, was significantly
associated with a higher risk of T2D.
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Table 2. Cont.
Author Study Design Study Population DietaryPattern/Intervention Follow-Up
Biological
Sample/Metabolomics
Approach
Metabolites Examined Main Conclusion
Yu et al.,
2018 [73]
Case–cohort
study in the
PREDIMED
study
n = 892
participants (251
T2D cases)
MedDiet groups: (MedDiet
+ EEVO and MedDiet +
mixed nuts.
Control group: low-fat diet
1 year Plasma Arginine, citrulline, ornithine,ADMA, SDMA, and NMMA
The one-year changes in arginine and the
arginine/ADMA ratio were negatively associated
with the risk of T2D 21. Positive changes in
ornithine and citrulline and negative changes in
SDMA and GABR were inversely associated with
concurrent changes in HOMA-IR 22
The MedDiet significantly modified the association
between one-year changes in NMMA and T2D risk.
Ruiz-Canela
et al., 2018
[72]
Case–cohort
study in the
PREDIMED
study
n = 945
participants (251
T2D cases)
MedDiet groups: (MedDiet
+ EEVO and MedDiet +
mixed nuts.
Control group: low-fat diet
3.8 years Plasma (baseline andafter 1 year)
The baseline BCAA 23 (leucine,
isoleucine and valine) and AAA 24
(phenylalanine and tyrosine) scores
were associated with a higher risk
of T2D. Increases in the BCAA
score after one year were associated
with higher T2D risk only in the
control group.
The MedDiet rich in EVOO significantly reduced
the levels of BCAA and attenuated the positive
association between plasma BCAA levels and
T2D incidence.
Papandreou
et al. 2018
[76]
Case–cohort
study in the
PREDIMED
study
n = 945
participants (251
T2D cases)
MedDiet groups: (MedDiet
+ EEVO and MedDiet +
mixed nuts.
Control group: low-fat diet
3.8 years Plasma (baseline andafter 1 year)
TMAO, L-carnitine, betaine, LPC
and LPE species, phosphocholine,
α-glycerophosphocholine, and
choline.
Higher baseline concentrations of
TMAO, L-carnitine, betaine,
α-glycerophosphocholine, and
several LPC 25 and LPE 26 species
were associated with a lower risk of
T2D development.
There was no significant difference in the
association of most of the one-year changes in the
metabolites with T2D risk in the MedDiet
intervention and control groups. The intervention
diets did not appear to significantly change the
study metabolite levels during the intervention.
Razquin et al.
(2018) [74]
Case–cohort
study in the
PREDIMED
study
n = 942
participants (250
T2D cases)
MedDiet groups: (MedDiet
+ EEVO and MedDiet +
mixed nuts.
Control group: low-fat diet
3.8 years Plasma (baseline andafter 1 year)
The baseline TAGs, DAGs, and PEs
were positively associated with
T2D risk. TAGs with odd-chain
fatty acids showed inverse
associations with T2D after
adjusting for total TAGs.
The one-year changes in the baseline metabolites
associated with T2D were not significant.
The changes in LP 27, PC-PL 28, SM 29, and CE
scores showed no apparent mediating effects.
Yu et al.,
2018 [75]
Case–cohort
study in the
PREDIMED
study
n = 892
participants (251
T2D cases)
MedDiet groups: (MedDiet
+ EEVO and MedDiet +
mixed nuts.
Control group: low-fat diet
3.8 years
Plasma
(baseline and after
1 year)
Targeted
Tryptophan, kynurenine, kynurenic
acid, 3-hydroxyanthranilic acid,
and quinolinic acid concentrations.
A KRS score was created.
The baseline tryptophan and one-year increases in
quinolinic acid were positively associated with
incident T2D. No effect of the MedDiet
was observed.
1 PREDIMED: Prevención con Dieta Mediterránea. 2 CVD: cardiovascular disease. 3 MedDiet: Mediterranean diet. 4 EVOO: extra virgin olive oil. 5 TMAO: trimethylamine N-oxide. 6 KRS:
kynurenine risk score. 7 d: shorthand notation of sphingolipids refer to 1,3 dihydroxy. 8 Glu: glutamate. 9 Gln: glutamine. 10 PC: phosphatidylcholines. 11 LysoPC: lysophosphatidylcholine.
12 CE: cholesterol esters. 13 TAG: long-chain triacylglycerols. 14 MAG: monoacylglycerols. 15 DAG: diacylglycerols. 16 PE: phosphatidylethanolamine. 17 hPC: hydroxyPC 18 ADMA:
asymmetric dimethylarginine. 19 SDMA: symmetric dimethylarginine. 20 NMMA: N-monomethyl-l-arginine. 21 T2D: type 2 diabetes. 22 HOMA-IR: homeostatic model assessment
of insulin resistance. 23 BCAA: branched-chain amino acids. 24 AAA: aromatic amino acids. 25 LPC: lyso- phosphatidylcholine. 26 LPE: lyso-phosphatidylethanolamine. 27 LP:
lysophospholipids. 28 PC-PL: phosphatidylcholine-plasmalogens. 29 SM: sphingomyelins.
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3. Microbiome and the Mediterranean Diet—The Present Status
The human gut is a highly diverse ecosystem consisting of 10–100 trillion microbial cells that
are mostly bacteria, but it also includes viruses, archaea, fungi, and others [46,80]. Quantitatively,
the total number of microbial genes in the gut or ‘gut microbiome’ outnumbers the host (human)
genome by 100 to 1 [81], and they may significantly impact the host’s physiology and ultimately
health. Recent advances in 16S rRNA-based sequencing technologies have facilitated species-level
identification of several of these non-culturable bacteria, with the majority belonging to the phyla
Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria [46,82,83]. Evidence suggests that there
are complex and dynamic associations between the host’s health, diet, lifestyle, and environment and
the composition of the host’s gut microbiome throughout the host’s lifespan [84]. Elucidating causal
relationships between intrinsic/extrinsic host factors on the gut microbiome and the impact of the
gut microbiome on metabolic functions, immunity, and health outcomes is currently an area of active
investigation globally [85–90].
It has been estimated that about 57% of the microbiome’s entire variation is due to dietary
habits, emphasizing the importance of diet in gut microbial ecology [91]. However, studies exploring
the relationship between the gut microbiome and diet have primarily focused on single nutrients
or foods and microbial response [92]. The literature describing the influence of dietary patterns,
a more comprehensive determinant of health, on the microbiome is very limited. For example,
with respect to the MedDiet, several studies have assessed the impact of olive oil [93], red wine [94],
whole grains [95], or other individual components on microbiota, but few have analyzed the MedDiet
pattern in its entirety [92]. Research on the MedDiet’s effects on the composition of the microbiome
and the contribution of the composition of the microbiome to MedDiet-related health outcomes will be
reviewed in the next two sections.
3.1. Mediterranean Diet Effects on General Microbiome Composition
Although microbiome changes in response to habitual dietary intake are not very well understood,
general associations between some dietary components/patterns and microbiota have been noted
in the literature. For example, elevated levels of Bacteroides sp. in the gut have been observed with a
Western-style dietary pattern that is rich in animal protein and saturated fat, while gut Prevotella sp.
have been shown to increase with the consumption of carbohydrates, especially from vegetables and
grains, or a more Mediterranean-style diet [46,96,97]. As described above, the physiological effects of
the microbiome are mediated by a combination of direct (physical) interactions of the microbe with
the host and indirect processes via the production of fermentation metabolites, de novo or from diet.
The profile of gut bacterial metabolites from fermentation is a function of both the bacterial ecology and
the substrate (i.e., fermentation of dietary fiber and other complex carbohydrates, which are prominent
in the MedDiet, or other plant-based foods results in short-chain fatty acids (SCFA) as opposed
to TMAO, which is usually seen in populations consuming diets rich in red meats). Table 3 lists
studies that evaluated the consumption of the MedDiet and its effects on the microbial composition in
healthy individuals. A recent, comparative, cross-sectional study explored the differences between two
groups of teenagers from different geographical locations (Egypt versus United States) with respect to
their microbial ecology, enterotype clustering function, and metabolite production in response to their
dietary intake. The authors found that in the group of Egyptian teenagers, who were primarily exposed
to a Mediterranean-style diet, all the gut microbial communities belonged to the Prevotella enterotype.
In contrast, almost all of the American teenagers in the study had gut microbial communities belonging
to the Bacteroides enterotype [96]. In an earlier 10-day controlled-feeding study that examined gut
microbial enterotypes as a result of high-fat/low-fiber or low-fat/high-fiber diets, Wu et al. found
similar results but additionally observed that the enterotype of the host microbiome remained unaltered
as the relative distributions (abundance) of bacterial phyla and genera levels changed within 24 h
of initiating a new diet pattern [97]. However, the magnitude of the changes was modest and was
not sufficient to switch the individuals between the enterotype clusters associated with protein/fat
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and carbohydrates, suggesting an association between a long-term Mediterranean-style diet and
enterotype partitioning [97].
In a randomized controlled trial, Djuric and colleagues explored the relationship between
carotenoid concentrations and mucosal colonic bacteria in healthy individuals at an increased risk
of colon cancer. Colonic biopsy samples (n = 88 at baseline, n = 82 after dietary intervention) were
obtained from the Healthy Eating study, in which the participants were assigned to one of two
dietary interventions, a MedDiet or a Healthy Eating diet for 6 months, with the primary difference
being the total fat content of the diet [98,99]. The researchers found that after the interventions,
the colonic mucosal bacteria was not significantly altered. However, 11 operational taxonomic
units were significantly associated with increased serum carotenoid concentrations, including lower
Firmicutes taxa and higher Proteobacteria abundance. Additionally, an increased abundance of
Prevotella sp. was observed in the highest carotenoid tertile [100]. These findings are consistent
with other “short-term” dietary intervention studies on the microbiome and suggest that long-term
dietary patterns may have a greater impact on changes in microbial ecology. The results from other
cross-sectional studies also evidence the higher abundance of Prevotella sp. with greater adherence
to the MedDiet [92,101]. De Filippis et al. found that Prevotella sp. was specifically associated with
fiber-degrading Firmicutes and increased levels of fecal SCFA, which has been associated with health
benefits [40]. Consistent with the previous section, higher urinary TMAO was associated with lower
adherence to the MedDiet. Another cross-sectional study assessing the association between the
MedDiet and microbial-derived phenolic compounds in stool samples (n = 74) found that subjects with
greater MedDiet scores had statistically higher levels of Clostridium cluster XIVa and Faecalibacterium
prausnitzii, which is a butyrate producer with proposed anti-inflammatory properties. This suggests
the MedDiet may produce more beneficial bacteria in the gut, which produces healthy metabolites.
They also found that Akkermansia sp., Bacteroides-Prevotella-Porphirimonas sp., and Bifidobacterium sp.
trended higher in the 42 subjects scoring ≥4 on the MedDiet score (range 0–8); however, there was a
smaller presence of the Lactobacillus sp. group in the greater MedDiet adherence group [102].
In an earlier cross-sectional study, Gutierrez-Diaz and colleagues explored the effects of the
MedDiet in 31 healthy subjects. The study found that several individual components of the MedDiet
were associated with an abundance of specific gut taxa. For example, cereals were linked to
Bifidobacterium sp. and Faecalibacterium sp., olive oil with Tenericutes and Dorea sp., red wine with
Faecalibacterium sp., vegetables with Rikenellaceae, Dorea sp., Alistipes sp., and Ruminococcus sp.,
and legumes with Coprococcus sp. The study also observed direct associations between the MedDiet
classifications and the abundance of the phylum Bacteroidetes and family Prevotellacceae. Additionally,
the genus Prevotella sp. was found to be inversely related to the phylum Firmicutes and the genus
Ruminococcus sp. [92]. This lower ratio of Firmicutes–Bacteroides with higher adherence to the MedDiet
was also shown in a recent study with 27 healthy individuals [103]. In agreement with the previous
research, higher concentrations of fecal propionate and butyrate were detected, corroborating the
potential mediated health effects of the MedDiet by SCFA production.
In summary, the MedDiet affects the composition of the gut microbiota (such as higher Prevotella
sp., Clostridium cluster XIVa, F. Pprausnitzii, Bacteroides, and Bifidobaterium sp. or lower Firmicutes
and Bacteroides) and can affect the functionality, diversity, and activity of some bacteria, whose
metabolites can have health benefits (such as SFCA). Further studies evaluating temporal changes
to the colonization, stability, and enterotype changes of the gut microbiota in clinical studies are still
warranted to establish a gut microbiota composition as a marker of MedDiet adherence.
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Table 3. Effects of a Mediterranean diet on microbiome composition.
Author Study Design Study Population Dietary Pattern/Intervention Follow-up Sample Microbiota Observed Results/Conclusion
Gutierrez-Diaz
et al., 2016 [92] Cross-sectional
Adults with a
non-declared pathology;
n = 31 (23 females, 8
males, mean age of 42.1
years
MedDiet 1 score (0–8 points; > 4 =
High adherence)
N/A Stool
Bifidobacterium, Faecalibacterium,
Tenericutes, Dorea, Rikenellaceae,
Alistipes, Ruminococcus
(Lechnospiraceae family),
Coprococcu, Bacteroidetes,
Prevotel-lacceae, Prevotella, and
Firmicutes
The MedDiet score was associated with a
higher abundance of Bacteroidetes,
Prevotel-laceae, and Prevotella and a lower
concentration of Firmicutes and
Lachnospiraceae.
Gutierrez-Diaz
et al., 2017
[102]
Cross-sectional
Healthy men (n = 20) and
women (n = 54) older than
50 years of age
MedDiet N/A Stool
Akkermansia,
Bacteroides-Prevotella-Porphiromonas,
Bifidobacterium, Clostridium cluster
XIVa, Lactobacillus group, and F.
prausnitzii
Higher levels of Clostridium cluster XIVA
and F. prausnitzii were found in subjects
with MDS 2 scores ≥4 and were positively
correlated with fecal concentrations of
benzoic and 3-hydroxyphenylacetic acids
and the intake of polyphenols and fibers.
De Filippis et
al., 2016 [101]
Cross-sectional
study
Healthy Volunteers
n = 153
MedDiet
Vegan
Vegetarian
Omnivore
N/A Stool,urine
Lachnospira,
Prevotella,
Roseburia, and
Ruminococcus
Plant-based diets appear to increase fecal
SCFAs, while Prevotella specifically was
associated with fiber-degrading Firmicutes.
Higher urinary trimethylamine oxide
levels were found to be higher in those
with lower MedDiet adherence.
Beneficial microbiome-related metabolic
profiles were associated with the increased
consumption of plant-based foods,
consistent with a MedDiet.
Garcia-Mantrana
et al., 2018
[103]
Cross-sectional
study
Healthy individuals n =
27, mean age 39.5 years MedDiet N/A
Stool
samples
Enterobacteriaceae family,
Bifidobacterium group,
Bacteroides-Prevotella-Porphyromonas
group, Bacteroides fragilis group,
Blautia coccoides group,
Methanobrevibacter smithii, and
Faecalibacterium prausnitzii
A higher ratio of Firmicutes–Bacteroidetes
was related to lower adherence to the
MedDiet, and greater presence of
Bacteroidetes was associated with lower
animal protein intake. Better adherence to
the MedDiet was associated with
significantly higher levels of total SCFA 3.
Shankar et al.,
2017 [96]
Comparative
cross-sectional
stud
Healthy Egyptian male
teenagers n = 28, mean
age 13.9 years
Healthy American male
teenagers n = 14, mean
age 12.9 years
MedDiet
Western diet N/A Stool
Egyptian: Gammaproteobacteria,
Methanobacteria, Prevotella,
Megasphaera, Eubacterium,
Mitsuokella, Catenibacterium
U.S.: Clostridia, Verrucomicrobia,
Bacteroides, Ruminococcus,
Coprococcus, Blautia, Bilophila,
Akkermansia, and Faecalibacterium,
Egyptian gut microbial communities
belonged to Prevotella in all the subjects
with increased polysaccharide-degrading
microbes and end products of
polysaccharide fermentation.
United States (US) gut microbial
communities mostly belonged to
Bacteroides with increased proteolytic
microbes and end products of protein and
fat metabolism.
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Table 3. Cont.
Author Study Design Study Population Dietary Pattern/Intervention Follow-up Sample Microbiota Observed Results/Conclusion
Djuric et al.,
2018 [100]
Randomized
control trial
n = 88 baseline samples
n = 82 post-intervention
(men and women)
Mean age 53 years
MedDiet (30% kcals form fat,
PUFA/SAT/MUFA 4 ratios of 1:2:5,
foods high in n-3 fatty acids
2x/week, 3 servings/day whole
grains, 7–9.5 cup s/day F 5+V 6)
including at least one cup dark
green or orange F or V).
Healthy Eating diet (5.5 cup
servings/day F + V, 3 s/day whole
grains, <10% kcals from sat. fat.
6 months
Blood,
colon
biopsy
Firmicutes, Proteobacteria,
Lachnospiraceae, Blautia, Roseburia,
Prevotella, and Bacteroides,
A total of 11 operational taxonomic units
were significantly associated with
increased serum carotenoid levels. The
Bacteria in the colonic mucosa was
resistant to change after both diet
interventions
The intestinal microbiota did not show
significant changes after 6 months of diet
intervention; however, an abundance of
specific OTUs 7 was significantly
associated with serum carotenoid
concentrations at the baseline, suggesting
that long-term dietary exposures may have
more of an influence on bacteria in the
colonic mucosa.
1 MedDiet: Mediterranean diet.2 MDS: Mediterranean Diet Score. 3 SCFA: Short Chain Fatty Acids. 4 PUFA/SAT/MUFA: polyunsaturated fatty acids/saturated fatty
acids/mono-unsataurated fatty acids: 5 F: Fruits. 6 V: Vegetables, 7 OTUs: Operational Taxonomic Unit.
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3.2. Microbiome, the Mediterranean Diet, and the Association with Health
While extensive research exists in the literature regarding the health benefits of following a
MedDiet pattern, there is limited knowledge regarding the MedDiet’s impact on microbiome-mediated
disease outcomes. In this section, the literature on microbiome changes as they relate to MedDiet
consumption in individuals with known diseases and the contribution of microbiome changes to
disease risk will be reviewed and summarized in Table 4.
Emerging evidence is showing that the adherence to a MedDiet is associated with more gut
microbial diversity. In the CORonary Diet Intervention with Olive Oil and Cardiovascular PREVention
(CORDIOPREV) study, 138 participants with metabolic syndrome (MetS) and 101 without MetS were
randomized into two groups. For 2 years, both groups underwent either a MedDiet or a low-fat diet
intervention. At basal time, a higher abundance of Bacteroides, Eubacterium and Lactobacillus generas
were found while Bacteroides fragilis group, Parabacteroides. distasonis, Bacteroides thetaiotaomicron,
Faecalibacterium prausnitzii, Fusobacterium. nucleatum, Bifidobacterium. longum, Bifidobacterium adolescentis,
Ruminococcus flavefaciens subgroupm and Eubacterium rectale were decreased in the participants with
MetS when compared to those without. After the two-year intervention, MedDiet adherence increased
the abundance of P. distasonis, B. thetaiotaomicron, F. prausnitzii, B. adolescentis, and B. longum in the MetS
patients, suggesting that a long-term MedDiet partially restored the dysbiosis in the gut microbiota in
the MetS patients, although the MetS persisted.
In another study conducted by the same research team, the effects of both a MedDiet and a low-fat
diet were examined but this time on the restoration of the microbiome in three different groups of
participants. A total of 106 subjects were evaluated: 33 were obese with MetS, 32 were obese without
MetS, and 41 were not obese and did not have MetS. The researchers found that the MedDiet and
low-fat diet consumption restored the microbiota in the MetS–obese participants to the gut microbiome
found in metabolically healthy people. However, no significant changes in gut microbial composition
occurred if MetS was absent (non-MetS–non-obese or non-MetS–Obese). Specifically, the study showed
that the Firmicutes/Bacteroidetes ratio (which has been linked to obesity) was related to the presence
or absence of metabolic traits and not with obesity itself. The Met–Obese group, previously described
with a reduction of genera with saccharolytic activity, showed increases in Bacteroides, Prevotella (both
forming bacteroidetes phylum), Faecalibacterium, Roseburia, Ruminococcus generas, and P. distasonis
and F. prausnitzii, a decreasing Firmicutes/ Bacteroidetes ratio, and no effect on the abundance of
Streptococcus or Clostridium. This is important because the restoration of saccharolytic activity
genera are associated with an increase in fermentation capacity to SCFA, for which health benefits
have previously been described. Consistent with those results, an increased abundance of Roseburia
sp. and Oscillospira sp. and insulin sensitivity were found in 20 obese subject after following a
one-year MedDiet intervention [104]. This butyrate-producing genus (Roseburia) has been found to
have anti-inflammatory effects and has a lower abundance in T2D [105,106]. Interestingly, F. prausnitzii,
which in the previous literature had been significantly increased with MedDiet consumption [102,107],
increased significantly only in the low-fat diet group. This study also showed that some changes
in fecal and plasma metabolites could also be linked to changes in gut microbiota [102]. Overall,
the results of this study suggested that a MedDiet could be used to prevent and manage T2D, although
more research is necessary to associate these therapeutic effects with microbiome-related factors [104].
Other studies exploring the MedDiet’s influence on inflammation associated with Crohn’s disease
(CD) found that 6 weeks of MedDiet intervention had no significant effect on the microbial ecology
relative to the control group. However, a trend towards “normal” composition (Bacteroidetes and
Clostridium clusters IV and XIVa increased, and the abundance of Proteobacteria decreased as did
Bacillaceae) was found in this study. Notwithstanding the lower number of subjects (n = 8), shorter
duration, and absence of a significant alteration in the microbial ecology in this particular study,
it should be noted that study participants were already under dietary management of CD, which may
have altered their microbiota before the study [83]. Finally, Mitsou et al. explored the relationship
between MedDiet adherence with gut microbiota composition and gastrointestinal (GI) symptomology.
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A profiling analysis showed that participants with high adherence to the MedDiet had significantly
less Escherichia coli, a higher ratio of Bifidobacteria to E. Coli, and increased levels of Candida albicans
and SCFA [108]. Interestingly, the MedDiet was also correlated with the alleviation of undesirable GI
symptoms and fecal moisture.
The present literature reveals that consuming a global MedDiet leads to alterations in the
microbiome; however, the extent to which these changes occur likely depends on numerous factors.
The study duration, disease risk, progression and severity, and dietary adherence potentially impact the
observed microbial changes. Furthermore, smoking, alcohol consumption, physical activity, and other
lifestyle behaviors may also be important determinants in influencing gut microbial composition. It is
well known and widely accepted that consumers of healthy dietary patterns often engage in a variety
of positive health practices, thus restricting the credibility of intervention studies as an appropriate
evaluation method of the MedDiet’s microbial influence on health [92]. Further research is necessary
to better identify the general outcome of MedDiet consumption on the microbiome and to identify
contributing factors to microbial changes. Figure 2 provides a summary of the evidence of the previous
two sections.
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under each respective disease. ↓: decreased with the consumption of MedDiet. ↑: increased with
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Table 4. Mediterranean diet effects on the microbiomes of diseased subjects.
Design Participant Characteristics Dietary Pattern/Treatment Length Sample Microbiota Observed Results/Conclusion
Haro et al.,
2016 [109]
Randomized
control trial
n = 138 with metabolic
syndrome (MetS) and n = 101
without MetS; male and
female patients within the
CORDIOPREV study with
CHD 1, who had their last
coronary event over 6 months
before enrolling, in addition
to conventional treatment
for CHD,
MedDiet group:35% fat (22%
MUFA, 6% PUFA, 7% SAT).
Low-fat high-complex carb
(LFHCC) diet group: 28% fat
(12% MUFA, 8% PUFA,
8% SAT).
2 years Stool,blood
Bacteroides, Eubacterium,
Lactobacillus, Bacteroides fragilis
group, Parabacteroides distasonis,
Bacteroides thetaiotaomicron,
Faecalibacterium prausnitzii,
Fusobacter- ium nucleatum,
Bifidobacterium longum,
Bifidobacterium adolescentis,
Ruminococcus flavefaciens
subgroup, and
Eubacterium rectale
The long-term consumption of the
Mediterranean diet partially restores
the population of P. distasonis, B.
thetaiotaomicron, F. prausnitzii, B.
adolescentis and B. longum in MetS
patients although MetS persists.
Haro et al.,
2016 [104]
Randomized
control trial
n= 20, 40 total samples
collected (20 at the baseline,
20 post-intervention) from
obese men with CHD within
the CORDIOPREV study
MedDiet group: 35% fat (22%
MUFA, 6% PUFA, 7% SAT).
Low-fat high-complex carb
(LFHCC) diet group: 28% fat
(12% MUFA, 8% PUFA,
8% SAT).
1 year Blood,stool
Bacteroides, Prevotella, unknown
Lachnospiraceae,
Faecalibacterium, unknown
Clostridiales, unknown
Ruminococcaceae, Oscillospira,
Parabacteroides, and
unknown Bacteroidales
Both diet changes increased insulin
sensitivity and appeared to exert
protective effects on the development
of T2DM 2 based off of specific
changes in gut microbiota. Changes
in feces include mostly amino acids,
peptides, and shingolipid
metabolism, which may be linked to
changes occurring in the
gut microbiota.
Haro et al.,
2017 [107]
Randomized
control trial
n = 33 obese patients with
severe MetS–OB 3, n = 32
obese patients without
non-MetS–OB, and 41
non-obese subjects
(non-MetS–non-OB).
MedDiet group: 35% fat (22%
MUFA, 6% PUFA, <10% SAT).
Low-fat diet group: <30%
total fat (<10% SAT., 12–14%
MUFA, 6–8% PUFA).
2 years Stool
Actinobacteria, Bacteroidetes,
Firmicutes, Bacteroides,
Prevotella, Roseburia,
Faecalibacterium, Ruminococcus,
Streptococcus, Clostridium, P.
distasonis, and F. prausnitzii
Both diets were associated with
partially restored gut microbiome
dysbiosis, converting MetS-OB
microbiota patterns to microbiota
patterns similar to those found in
(metabolically) healthy people, after
2 years of nutrition intervention in
participants with coronary heart
disease. The degree of participants’
metabolic dysfunction may alter the
effectiveness of nutrition therapy.
Marlow
et al., 2014
[83]
Non-randomized
trial
n = 8 Crohn’s patients with no
history of bowel surgery who
were not taking prednisone or
similar anti-inflammatory
medication and had no
changes in medication over
the last 3 months.
MedDiet 6 weeks Stool,blood
Firmicutes, Bacteroidetes,
Actinobacteria, Proteo- bacteria,
Fusobacteria, and
Verrucomicrobia
The Mediterranean-inspired diet
appeared to benefit the health of
people with Crohn’s disease. The
participants showed a trend for
reduced markers of inflammation
and normalization of the microbiota;
however, the changes were
not significant.
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Table 4. Cont.
Design Participant Characteristics Dietary Pattern/Treatment Length Sample Microbiota Observed Results/Conclusion
Mitsu et al.,
2017 [108] Cross-sectional
n = 120 Men and women,
age 18–65 years
MedDiet Tertiles of adherence
based on MedDiet score:
Low tertile score = 19–30
(n = 31)
Medium tertile score = 31–33
(n = 29)
High tertile score = 34–41
(n = 40)
N/A Stool E. coli, bifidobacteria,and Candida albicans
The findings support a link between
MedDiet adherence and the gut
microbiota profile.
Those with high adherence had lower
E. coli counts, a higher
bifidobacterial/E. coli ratio, and
increased levels and prevalence of
Candida albicans when compared to
those with low adherence
Garcia-Mantrana
et al., 2018
[103]
Cross-sectional
study
Healthy individuals n = 27,
mean age 39.5 years MedDiet
Stool
samples
Enterobacteriaceae family,
Bifidobacterium group,
Bacteroides-Prevotella-Porphyromonas
group, Bacteroides fragilis group,
Blautia coccoides group,
Methanobrevibacter smithii, and
Faecalibacterium prausnitzii
Butyricimonas, Desulfovibrio, and
Oscillospira genera were associated
with a BMI of <25 and the genus
Catenibacterium was associated with a
higher adherence to the MedDiet.
1 CHD: coronary heart disease.2 T2DM: type II diabetes.3 OB: Obese subjects.
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4. Conclusions, Implications, and Future Directions
In recent years, high-throughput metabolomic and microbiome analysis techniques have emerged
as promising, objective tools to aid and complement the traditional epidemiology methods used to
assess diet. Due to the complexity of the diet–disease relationship, assessing both the metabolome
and microbiome of an individual may help provide information regarding dietary patterns in light
of the information provided in Food Frequency Questionarries (FFQs), food diaries, and interviews.
In addition, metabolomics can help to document compliance in dietary intervention studies, although
it should be recognized that unlike in drug studies, blinding and/or randomization of the participants
may be difficult in nutrition research. Currently, metabolomic literature has identified numerous
metabolites related to the consumption of individual dietary components and has begun to identify
metabolomic patterns in response to global dietary patterns. Identifying specific physiologically
relevant small metabolites derived after the ingestion of unique diets may provide insight into health
status and merits further investigation. In order for metabolites to assist in dietary assessment,
they must be stable and sensitive to dietary consumption and also reflect long-term usual intake.
Subtle and intermittent fluctuations in metabolite concentrations, as well as a short half-life, may not
only pose analytical challenges, but also may only be indicative of recent dietary intake and not a
global dietary pattern.
The current MedDiet–microbiome literature, though promising, does not provide conclusive
evidence on the relative contributions of the gut microbiome on the beneficial health outcomes
associated with the MedDiet [110]. Emerging evidence from the literature points to the prominent role
of the microbiome in human health, although the causality and governing mechanisms remain unclear.
Moreover, differences in microbial profiles appear to be dependent upon several factors including
age, habitual dietary consumption, overall health, disease risk, and underlying pathology [110–112].
Therefore, at this time, the analysis of microbial composition, though promising, cannot be
recommended as a stand-alone tool for either dietary assessment or related health outcomes. It can,
however, complement and strengthen the existing tools, and it holds significant potential as a promising
tool in the future. Further research that comprehensively examines the relationships between dietary
patterns, microbial changes, and disease outcomes should also focus on using standardized methods
and reporting processes that are transferrable across different research groups [110]. Furthermore,
systemic approaches that integrate both metabolomics and the microbiome will help researchers to
understand their complex interrelationships and interactions with health. The evidence shows that
some metabolites (e.g., SCFA production) are mediated by the gut microbiome [40,112]. For example,
the CORDIOPREV study found that changes in the metabolites in feces were accompanied by changes
in the gut microbiota [101], and a recent investigation within the Malmö Offspring Study found an
association between four gut microbiota genera and body mass index-predicted plasma metabolites,
including glutamine and BCAAs [113]. Thus, evidence is emerging in this regard, and recent and
future studies will further elucidate these relationships/associations (such as the potential effect of the
microbial amino acid metabolism on obesity [114]).
It is undeniable that emerging, big data, multi-omics approaches will improve our understanding
of the distinctive metabolomics/microbial characteristics that contribute to our overall health and
disease risk at an individual and population level. Each method is accompanied by its own strengths
and limitations, but when used together, subjective dietary assessments, metabolomic assessments,
and microbiome assessments may be able to provide a much more complete picture of the diet–health
relationship. This knowledge can have a significant impact on the shaping of policy and the
advancement of targeted precision/personalized nutrition-based therapeutic approaches for the
prevention and management of chronic diseases [110,115].
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/1/207/s1,
Table S1: Main findings and evidence from metabolites associated with food.
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